中国急性缺血性卒中早期血管内介入诊疗指南对比分析

Comparative analysis of Chinese guidelines for the endovascular treatment of acute ischemic stroke

脑血管病在我国发病率很高,其中以急性缺血性卒中最为常见,其脑组织缺血缺氧引起的神经功能损伤及并发症对现代人的生活质量造成了严重影响。目前关于急性缺血性卒中介入治疗的临床研究在适用范围、治疗理念及技术层面等方面有新一步进展。中华医学会神经病学分会分别于2018年、2022年组织制定了《中国急性缺血性卒中早期血管内介入诊疗指南》,对认识和诊疗急性缺血性卒中具有非常重要的临床意义。本文将2018年指南及2022年指南内容进行对比及分析,明确缺血性卒中早期血管内介入诊疗变化,以利于临床诊治。

Cerebrovascular disease has a high incidence rate in my country,among which acute ischemic stroke(AIS)is the most common.The cerebral ischemia-induced brain injury and its complications seriously affect the quality-of-life of modern people.At present,clinical research regarding AIS interventional treatment have made new progress in terms of applicable scope,medical perspective,treatment technology.The Neurology Branch of the Chinese Medical Association organized and formulated the"Chinese guidelines for the endovascular treatment of acute ischemic stroke"in 2018 and 2022,which have great clinical significance for understanding and diagnosis of AIS.In this article,A comparative analysis will be performed in 2018 and 2022 guidelines to clarify the changes in early endovascular interventional,which might be beneficial to clinical diagnosis and treatment.